Ani Pharmaceuticals (ANIP) Total Current Liabilities (2016 - 2026)
Ani Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $278.1 million for Q4 2025.
- On a quarterly basis, Total Current Liabilities rose 43.02% to $278.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $278.1 million, a 43.02% increase, with the full-year FY2025 number at $278.1 million, up 43.02% from a year prior.
- Total Current Liabilities hit $278.1 million in Q4 2025 for Ani Pharmaceuticals, up from $270.6 million in the prior quarter.
- Over the last five years, Total Current Liabilities for ANIP hit a ceiling of $278.1 million in Q4 2025 and a floor of $79.5 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $143.9 million across 5 years, with a median of $130.1 million in 2023.
- Biggest five-year swings in Total Current Liabilities: dropped 3.91% in 2022 and later skyrocketed 69.19% in 2025.
- Tracing ANIP's Total Current Liabilities over 5 years: stood at $87.5 million in 2021, then increased by 13.6% to $99.4 million in 2022, then skyrocketed by 46.3% to $145.5 million in 2023, then soared by 33.67% to $194.5 million in 2024, then skyrocketed by 43.02% to $278.1 million in 2025.
- Business Quant data shows Total Current Liabilities for ANIP at $278.1 million in Q4 2025, $270.6 million in Q3 2025, and $236.8 million in Q2 2025.